CVE-2026-94033

LOWPre-NVD 3.53.5—
EchelonGraph scoreHIGH confidence

Score 3.5 from GitHub Security Advisory (severity: LOW) published 2026-09-20. a secondary CVSS source baseline 3.5; sources differ by 0.0.

Triggered by: GitHub Security Advisory CVSS
Sources: epss, ghsa, secondary
Trending — 5 sources updated this weekElevated
3.5EG
EchelonGraph verdictMonitorLow exploitation likelihood right now — keep watching.
  • Lower severity and no public exploit yet
CISA-KEV: Not listedEPSS PROB: 0%CVSS: 3.5Exploit: Elevated riskExposed: 0

No vendor fix yet — apply a workaround or compensating control (WAF / firewall / segmentation) and watch for a patch.

A vulnerability has been found in SourceCodester Drug Recommendation System 1.0. This vulnerability affects unknown code of the file /drug_recommender/Admin/add_user of the component User Management. Such manipulation of the argument txtname/txtemail/txtpassword leads to cross site scripting. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be used.

CVSS v3
3.5
EG Score
3.5(high)
EG Risk
32(Track)
EG Risk 32/100SSVC: Track

EG Risk is EchelonGraph's 0–100 priority score: it fuses intrinsic severity with real-world exploitation and automatability so you can rank equal-severity CVEs and fix the most dangerous first. Higher = act sooner. Distinct from the 0–10 EG Score (severity).

How it’s computed
Severity35% × 45%
Exploitation40% × 40%
Automatability0% × 15%
Action: Routine — remediate on your standard cadence.
EPSS PROB
0%
EPSS %ILE
26%
KEV
Not listed

Published

September 20, 2026

Last Modified

September 21, 2026

References (6)

Vendor Advisories for CVE-2026-94033(1)

These vendors published their own advisory mentioning this CVE — often with vendor-specific remediation steps + affected product lists not in NVD.

Weakness Classification(2)

MITRE Common Weakness Enumeration — the root-cause categories this CVE belongs to.

Data Freshness Timeline

(refreshed 18× in last 7d / 18× in last 30d)

Each row is a source pipeline that fetched or updated this CVE on that date, with what changed. For example, "NVD update" means NVD published or revised its analysis for this CVE; "MITRE cvelistV5" means we ingested or refreshed it from the CNA feed. Most recent first.

  1. 2026-09-24 21:46 UTCEG score recompute
  2. 2026-09-24 21:46 UTCGHSA enrichment
  3. 2026-09-24 14:04 UTCEPSS rescore
  4. 2026-09-23 17:54 UTCEPSS rescore
  5. 2026-09-22 16:01 UTCEPSS rescore
  6. 2026-09-21 21:23 UTCEG score recompute
  7. 2026-09-21 21:23 UTCGHSA enrichment
  8. 2026-09-21 21:22 UTCNVD updateCVSS v4 → 2
  9. 2026-09-21 21:09 UTCEPSS rescore
  10. 2026-09-21 20:25 UTCEG score recompute
  11. 2026-09-21 20:25 UTCGHSA enrichment
  12. 2026-09-21 20:23 UTCMITRE cvelistV5CVSS v4 → 5.1
  13. 2026-09-21 13:40 UTCGHSA enrichment
  14. 2026-09-20 15:31 UTCEG score recompute
  15. 2026-09-20 15:31 UTCGHSA enrichment
  16. 2026-09-20 15:31 UTCNVD updateCVSS v4 → 2
  17. 2026-09-20 14:46 UTCEG score recompute
  18. 2026-09-20 14:46 UTCMITRE cvelistV5first tracked

Related CVEs(same CWE)

Frequently asked(5)

What is CVE-2026-94033?
CVE-2026-94033 is a low vulnerability published on September 20, 2026. A vulnerability has been found in SourceCodester Drug Recommendation System 1.0. This vulnerability affects unknown code of the file /drugrecommender/Admin/adduser of the component User Management. Such manipulation of the argument txtname/txtemail/txtpassword leads to cross site scripting. It is…
When was CVE-2026-94033 disclosed?
CVE-2026-94033 was first published in the National Vulnerability Database on September 20, 2026, with the most recent update on September 21, 2026. EchelonGraph re-ingests CVE updates from NVD on a 2-hour cycle, so this page reflects the latest published state.
Is CVE-2026-94033 actively exploited?
CVE-2026-94033 is not currently on CISA's Known Exploited Vulnerabilities catalog. FIRST EPSS estimates a 0% probability of exploitation in the next 30 days, which ranks it in the top 74.4% of all scored CVEs.
What is the CVSS score of CVE-2026-94033?
CVE-2026-94033 has a CVSS v3 base score of 3.5 (NVD).
How do I remediate CVE-2026-94033?
Patch to the fixed version published by the affected vendor. Where vendor advisories exist for CVE-2026-94033, EchelonGraph cross-links them in the Vendor Advisories panel below — those typically contain the canonical remediation steps, fixed version numbers, and any vendor-specific mitigations.

Dependency Blast Radius

Explore the affected products and dependency analysis for CVE-2026-94033

Explore →

Is Your Infrastructure Affected by CVE-2026-94033?

EchelonGraph automatically scans your cloud infrastructure and maps CVE exposure using blast radius analysis.

Book a Demo →Browse All CVEs